Markets may be trading near record highs, but that doesn’t mean every stock is riding the wave. In fact, some well-known names have been left behind — and that’s exactly where Switzer Report’s Paul Rickard sees potential opportunity.

Did you know?

Over at The Switzer Report, Peter Switzer, Paul Rickard and a host of market experts dive deep into the market to find the value others have missed. Becoming a subscriber gets you access to the kind of content you won't find anywhere else, and goes much deeper than what you'll read below! Check it out.

In this week’s episode of Switzer Investing TV, Rickard outlined four “beaten-up” stocks that could reward patient investors willing to go hunting for value.

1. Treasury Wine Estates (ASX: TWE)

The wine giant behind labels like Penfolds has seen its share price dip below $8, with analysts tipping around 21% upside from here. While the broader wine industry is facing headwinds — especially with younger consumers drinking less — Rickard still sees long-term value in Treasury’s brand portfolio.

“It still has some great brands… [and] below $8, I think it’s value,” Rickard said. The company has already downgraded its earnings guidance, meaning expectations are low — and any upside surprise could kick the stock into gear.

2. Ramsay Health Care (ASX: RHC)

Once an $80 stock, Ramsay is now trading around $38, down significantly thanks to a slow post-COVID recovery in hospital admissions and a mixed bag of offshore investments.

“The market sort of thinks most of its offshore investments have been duds,” Rickard noted, citing challenges in European healthcare systems. Despite this, he still sees potential. “There’s value there,” he said, particularly for long-term holders who can wait out the rough patch.

3. CSL (ASX: CSL)

One of Australia’s biggest healthcare success stories, CSL has stalled while the broader market has rallied. Trading at around $242, analysts believe it could climb as high as $318 — a 30% premium.

“It really hasn’t been able to go up,” Rickard admitted, pointing to uncertainty around US pharmaceutical policy and Donald Trump’s return to the political spotlight. But he’s optimistic: “CSL looks good… The health sector generally looks like good value.”

4. Amcor (ASX: AMC)

It may not get the headlines, but Amcor is a steady earner in the packaging space — and that’s exactly the appeal. Shares have slipped to $14.70, with analysts forecasting a 20% upside. The company also pays a reliable quarterly dividend of around 4.5% (unfranked), which adds to its defensive appeal.

“It’s a boring stock… but it’s pretty reliable,” Rickard said. He praised the company’s recent US acquisition and thinks it’s a solid pick for portfolios focused on income and stability.

In a market where the big names have already had their run, Rickard’s picks are all about finding value where others aren’t looking — and being patient enough to let that value unfold.